$IBRX
ImmunityBio, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020052488 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q4
Revenue $151.0K $436.0K $9.000K
YoY Change 1158.33% 2464.71% 28.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.60M $18.35M $4.120M
YoY Change 386.86% 300.59% -21.52%
% of Gross Profit
Research & Development $35.77M $33.01M $12.00M
YoY Change 196.81% 159.27% 1.01%
% of Gross Profit
Depreciation & Amortization $2.400M $1.020M $2.210M
YoY Change 9.09% -53.64% -20.79%
% of Gross Profit
Operating Expenses $66.03M $51.35M $16.12M
YoY Change 310.7% 196.61% -9.06%
Operating Profit -$65.88M -$50.92M -$16.11M
YoY Change 310.07% 194.38% -9.08%
Interest Expense $2.226M $2.123M $310.0K
YoY Change 430.0% 333.27% -11.43%
% of Operating Profit
Other Income/Expense, Net -$1.993M -$1.056M $100.0K
YoY Change -511.78% -271.43% -200.0%
Pretax Income -$67.87M -$51.97M -$15.70M
YoY Change 335.59% 211.58% -10.13%
Income Tax -$1.700M $45.00K -$60.00K
% Of Pretax Income
Net Earnings -$65.60M -$51.44M -$15.64M
YoY Change 321.04% 208.35% -9.8%
Net Earnings / Revenue -43445.7% -11797.94% -173788.89%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17 -$203.4K -$158.8K
COMMON SHARES
Basic Shares Outstanding 381.8M shares
Diluted Shares Outstanding 381.8M shares

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $146.0M $110.6M $111.9M
YoY Change 120.93% 31.59% 50.97%
Cash & Equivalents $84.69M $115.2M $75.80M
Short-Term Investments $61.35M $7.900M $36.14M
Other Short-Term Assets $90.00K $67.00K $24.00K
YoY Change 87.5% 31.37% -42.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $98.02M $115.3M $55.76M
YoY Change 36.87% 32.46% -37.19%
LONG-TERM ASSETS
Property, Plant & Equipment $55.86M $58.62M $60.50M
YoY Change -10.12% -9.95% -21.31%
Goodwill
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments $10.00M $9.300M $10.80M
YoY Change -6.54% -13.08% -23.94%
Other Assets $2.029M $2.600M $4.386M
YoY Change -38.22% 738.71% 187.23%
Total Long-Term Assets $82.52M $80.90M $87.37M
YoY Change -6.85% -8.74% -6.24%
TOTAL ASSETS
Total Short-Term Assets $98.02M $115.3M $55.76M
Total Long-Term Assets $82.52M $80.90M $87.37M
Total Assets $180.5M $196.2M $143.1M
YoY Change 12.69% 11.67% -21.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.160M $4.000M $1.749M
YoY Change 193.33% 107.58% -37.38%
Accrued Expenses $5.497M $7.449M $5.343M
YoY Change -33.77% 15.2% -74.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $800.0K
YoY Change -20.0%
Total Short-Term Liabilities $20.66M $17.00M $11.56M
YoY Change 65.05% 36.77% -57.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $11.30M $9.500M $10.90M
YoY Change -3.42% -20.83%
Total Long-Term Liabilities $11.30M $9.500M $10.90M
YoY Change -3.42% -20.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.66M $17.00M $11.56M
Total Long-Term Liabilities $11.30M $9.500M $10.90M
Total Liabilities $31.90M $26.50M $22.44M
YoY Change 31.54% 8.49% -37.56%
SHAREHOLDERS EQUITY
Retained Earnings -$722.4M -$700.7M -$662.2M
YoY Change 11.73% 11.05% 11.3%
Common Stock $783.0M
YoY Change 5.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $148.6M $169.7M $120.7M
YoY Change
Total Liabilities & Shareholders Equity $180.5M $196.2M $143.1M
YoY Change 12.67% 11.67% -21.34%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q4
OPERATING ACTIVITIES
Net Income -$65.60M -$51.44M -$15.64M
YoY Change 321.04% 208.35% -9.8%
Depreciation, Depletion And Amortization $2.400M $1.020M $2.210M
YoY Change 9.09% -53.64% -20.79%
Cash From Operating Activities -$18.28M $1.990M -$14.88M
YoY Change 10.32% -111.82% 6.06%
INVESTING ACTIVITIES
Capital Expenditures -$1.700M -$220.0K -$680.0K
YoY Change 314.63% -77.78% -66.67%
Acquisitions
YoY Change
Other Investing Activities -$54.55M $15.32M $12.84M
YoY Change -406.63% 23.85% -28.51%
Cash From Investing Activities -$56.25M $15.10M $12.17M
YoY Change -423.83% 32.69% -23.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -490.0K 87.34M -60.00K
YoY Change 1125.0% -17225.49% -83.78%
NET CHANGE
Cash From Operating Activities -18.28M 1.990M -14.88M
Cash From Investing Activities -56.25M 15.10M 12.17M
Cash From Financing Activities -490.0K 87.34M -60.00K
Net Change In Cash -75.02M 104.4M -2.770M
YoY Change -9971.05% -1852.18% -283.44%
FREE CASH FLOW
Cash From Operating Activities -$18.28M $1.990M -$14.88M
Capital Expenditures -$1.700M -$220.0K -$680.0K
Free Cash Flow -$16.58M $2.210M -$14.20M
YoY Change 2.6% -113.95% 18.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15508000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61353000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
43-1979754
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
36144000
dei Entity Address Address Line1
EntityAddressAddressLine1
3530 John Hopkins Court
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8977000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37507
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6160000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1749000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5497000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5343000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020Q3 us-gaap Assets Current
AssetsCurrent
98018000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
769000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60501000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27688000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
55757000
CY2020Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
9253000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
633-0300
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1472000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14602000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11729000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2029000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4386000
CY2020Q3 us-gaap Assets
Assets
180535000
CY2019Q4 us-gaap Assets
Assets
143123000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1497000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55864000
CY2019Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
9253000
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1356000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
486000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12052000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4711000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4025000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-15581000
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
9000
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21995000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
16077000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21927000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16065000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
66000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
433000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
153000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-15581000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108246579
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98331695
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49934000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-2000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-4000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44227000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37781000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16603000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13949000
us-gaap Operating Expenses
OperatingExpenses
60830000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5351000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3206000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2299000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
775000
us-gaap Net Income Loss
NetIncomeLoss
-50148000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92791644
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21776000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15550000
us-gaap Net Income Loss
NetIncomeLoss
-60251000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101853047
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20663000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11559000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11250000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10885000
CY2019Q4 us-gaap Liabilities
Liabilities
22444000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98460404
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98460404
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
782965000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-105000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-662191000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120679000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143123000
us-gaap Revenues
Revenues
90000
us-gaap Revenues
Revenues
34000
us-gaap Operating Expenses
OperatingExpenses
51730000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60740000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51696000
us-gaap Investment Income Net
InvestmentIncomeNet
319000
us-gaap Investment Income Net
InvestmentIncomeNet
1336000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
19000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50182000
us-gaap Net Income Loss
NetIncomeLoss
-60251000
us-gaap Net Income Loss
NetIncomeLoss
-50148000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-19000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
27000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-14000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
210000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-321000
nk Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
-173000
CY2020Q3 nk Stock Offering Costs
StockOfferingCosts
4373000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
31000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
214000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21793000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60263000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18470000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
751000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
271000
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-2000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-17000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
148622000
nk Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
288000
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-4000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
169653000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
711000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
353000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21776000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120679000
nk Stock Offering Costs
StockOfferingCosts
4373000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86302000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
917000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-485000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-12000
us-gaap Net Income Loss
NetIncomeLoss
-60251000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
148622000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
151269000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
277000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-40000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-15581000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
135956000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
146006000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2150000
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
35151000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4070000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-66000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
501000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
214000
us-gaap Net Income Loss
NetIncomeLoss
-50148000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
135956000
us-gaap Profit Loss
ProfitLoss
-60251000
us-gaap Profit Loss
ProfitLoss
-50148000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6864000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6803000
nk Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
2290000
nk Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
1925000
us-gaap Share Based Compensation
ShareBasedCompensation
1472000
us-gaap Share Based Compensation
ShareBasedCompensation
2150000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-425000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-2000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-5000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
869000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2291000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9176000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-116000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2961000
nk Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
4253000
nk Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
342000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1574000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-11622000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
1091000
CY2020Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
100000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
47000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
339000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
188000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-12000
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
31000
CY2020Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
49000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
829000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-839000
nk Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2654000
nk Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2339000
us-gaap Depreciation
Depreciation
6900000
us-gaap Depreciation
Depreciation
6200000
CY2020Q3 us-gaap Security Deposit
SecurityDeposit
113000
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
113000
CY2019Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
19000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2029000
CY2020Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1838000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2002000
CY2020Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1113000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1064000
CY2020Q3 nk Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
627000
CY2019Q4 nk Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
281000
CY2020Q3 nk Accrued Franchise And Sales Use Taxes
AccruedFranchiseAndSalesUseTaxes
217000
CY2019Q4 nk Accrued Franchise And Sales Use Taxes
AccruedFranchiseAndSalesUseTaxes
200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47397000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46477000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2238000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3502000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
3000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
85581000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
76831000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
54080000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
87100000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
6582000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2529000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9293000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86302000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
917000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4070000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
35151000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
501000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
485000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
66000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86734000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38654000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12180000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1470000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15687000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27867000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27688000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18291000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
179000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
179000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27867000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18470000
us-gaap Interest Paid Net
InterestPaidNet
19000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
us-gaap Stock Issued1
StockIssued1
1233000
us-gaap Stock Issued1
StockIssued1
29000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5164000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
800000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-722400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47400000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
74000
CY2020Q3 nk Financing Obligation Current
FinancingObligationCurrent
2262000
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
18000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
449000
CY2020Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-381000
CY2019Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
13000
CY2020Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-2000
CY2019Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-4000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1325000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
15000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-4000
us-gaap Investment Income Interest
InvestmentIncomeInterest
795000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-474000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-2000
us-gaap Investment Income Net
InvestmentIncomeNet
319000
us-gaap Investment Income Net
InvestmentIncomeNet
1336000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
16000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> candidates developed by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will require approvals or clearances from the U.S. Food and Drug Administration</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or international regulatory agencies prior to commercial sales. There can be no assurance that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> candidates will receive any of the required approval</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or clearance</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ere</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be denied approval or clearance or any such approval or clearance w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be delayed, it would have a material adverse impact on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
CY2020Q3 nk Prepaid License Fees
PrepaidLicenseFees
216000
CY2019Q4 nk Prepaid License Fees
PrepaidLicenseFees
78000
CY2020Q3 nk Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
165000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4128302
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5780228
CY2020Q3 nk Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
3262000
CY2019Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
1021000
CY2020Q3 nk Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
2262000
CY2019Q4 nk Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
757000
CY2020Q3 nk Prepaid Services
PrepaidServices
825000
CY2019Q4 nk Prepaid Services
PrepaidServices
440000
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
657000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
372000
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
510000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
222000
CY2020Q3 us-gaap Prepaid Rent
PrepaidRent
422000
CY2019Q4 us-gaap Prepaid Rent
PrepaidRent
392000
CY2020Q3 nk Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
306000
CY2019Q4 nk Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
467000
CY2019Q4 nk Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
251000
CY2020Q3 nk Laboratory Equipment Deposit
LaboratoryEquipmentDeposit
162000
CY2019Q4 nk Laboratory Equipment Deposit
LaboratoryEquipmentDeposit
0
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
24000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8977000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14200
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2150000
CY2019Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
100000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2020Q3 nk Prepaid Software License Fees In Other Assets
PrepaidSoftwareLicenseFeesInOtherAssets
118000
CY2019Q4 nk Prepaid Software License Fees In Other Assets
PrepaidSoftwareLicenseFeesInOtherAssets
0
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4386000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80698000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79108000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24834000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18607000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55864000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60501000
CY2020Q3 us-gaap Depreciation
Depreciation
2400000
CY2019Q3 us-gaap Depreciation
Depreciation
2200000
CY2020Q3 nk Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
1570000
CY2019Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
4075000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
975000
CY2020Q3 nk Accrued Laboratory Equipment Supplies And Related Services
AccruedLaboratoryEquipmentSuppliesAndRelatedServices
635000
CY2020Q3 us-gaap Construction Payable Current
ConstructionPayableCurrent
164000
CY2019Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
0
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
181000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5497000
CY2019Q4 nk Accrued Laboratory Equipment Supplies And Related Services
AccruedLaboratoryEquipmentSuppliesAndRelatedServices
640000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
16601000
nk Operating Lease Payments Related To Options To Extend Lease Terms
OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms
3900000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
62122000
nk Available For Sale Securities Debt Securities Period
AvailableForSaleSecuritiesDebtSecuritiesPeriod
P0Y6M
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37642000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2019Q4 nk Financing Obligation Current
FinancingObligationCurrent
757000
CY2020Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
37000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2299000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
775000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
62134000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5343000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
424000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
66000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
433000
CY2020Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2017Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
8500000
CY2020Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
9300000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37641000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
33238000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
11021000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4245000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
8000
CY2019Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
12000000.0
CY2019Q3 us-gaap Legal Fees
LegalFees
500000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1000000.0
us-gaap Operating Lease Payments
OperatingLeasePayments
3200000
us-gaap Operating Lease Payments
OperatingLeasePayments
3300000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1625000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6563000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5607000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2545000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1083000
CY2020Q3 nk Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1729000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19152000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2551000
CY2015Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000.0
CY2020Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
18300000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
473586
nk Stock Repurchased And Retired Excluding Commissions During Period Value
StockRepurchasedAndRetiredExcludingCommissionsDuringPeriodValue
500000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
711000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
277000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1472000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
711000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
277000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1472000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2150000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
900000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
nk Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2019Q3 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
0
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
-34000

Files In Submission

Name View Source Status
0001564590-20-052488-index-headers.html Edgar Link pending
0001564590-20-052488-index.html Edgar Link pending
0001564590-20-052488.txt Edgar Link pending
0001564590-20-052488-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gs3pz0t2cv2v000001.jpg Edgar Link pending
gs3pz0t2cv2v000002.jpg Edgar Link pending
gs3pz0t2cv2v000003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nk-10q_20200930.htm Edgar Link pending
nk-10q_20200930_htm.xml Edgar Link completed
nk-20200930.xsd Edgar Link pending
nk-20200930_cal.xml Edgar Link unprocessable
nk-20200930_def.xml Edgar Link unprocessable
nk-20200930_lab.xml Edgar Link unprocessable
nk-20200930_pre.xml Edgar Link unprocessable
nk-ex101_92.htm Edgar Link pending
nk-ex102_93.htm Edgar Link pending
nk-ex103_94.htm Edgar Link pending
nk-ex104_390.htm Edgar Link pending
nk-ex311_7.htm Edgar Link pending
nk-ex312_8.htm Edgar Link pending
nk-ex321_11.htm Edgar Link pending
nk-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending